QualityStocks would like to highlight Ohr Pharmaceutical Inc. (OTCBB: OHRP), a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The company is focused on two lead compounds: Squalamine eye drops for the treatment of the wet form of age-related macular degeneration, and OHR/AVR118 for the treatment of cancer cachexia, currently being investigated in a Phase II trial.
In the company’s news last week,
Ohr Pharmaceutical announced that its existing shareholders have exercised 5,299,022 Series H warrants at $0.55 per warrant, resulting in net proceeds of $2.91 million.
The company offered shareholders 0.6 replacement warrants for every Series H warrant exercised, resulting in the aggregate issuance of 3,179,410 warrants exercisable at $1.20 for a five-year period; 95 percent of the outstanding Series H warrants were exercised in this transaction.
Ohr Pharmaceutical said it plans on using the proceeds for general corporate purposes, as well as to advance the clinical development of its compounds: Squalamine eye drops for the treatment of wet-AMD and neovascular ophthalmic disorders; and OHR/AVR118 for the treatment of cancer cachexia.
“This financing will allow us to comfortably achieve several upcoming milestones in our Squalamine eye drop and OHR/AVR118 clinical programs in the remainder of 2012 and 2013. We would also like to thank our shareholders for their continued support,” Dr. Irach B. Taraporewala, CEO of Ohr Pharmaceutical stated in the press release.
The Squalamine eye drop program for wet-AMD was awarded Fast Track designation by the FDA, and Ohr Pharmaceuticals will begin a phase II trial in the third quarter of 2012.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.